Business Context and Reporting Period
This Form 8-K Current Report was filed by Zimmer Biomet Holdings, Inc. on February 4, 2016, with the earliest event reported on that same date. The filing details a material definitive agreement involving a secondary offering of common stock by selling stockholders and a concurrent share repurchase by the Company.
Key Financial Metrics and Transaction Details
- Secondary Offering: Selling Stockholders (funds affiliated with The Blackstone Group L.P. and The Goldman Sachs Group, Inc.) sold 11,027,558 shares of common stock.
- Share Repurchase: The Company purchased 2,599,833 shares from the Underwriter (Barclays Capital Inc.) for an aggregate price of approximately $250 million.
- Proceeds: The Company will not receive any proceeds from the sale of shares by the Selling Stockholders.
- Transaction Completion: Both the sale by Selling Stockholders and the Company's repurchase were completed on February 10, 2016.
- Ownership Context: Prior to the transaction, Selling Stockholders collectively held more than 7.3% of outstanding shares and may have shared beneficial ownership of more than 14.9%.
Note: This filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or debt levels.
Material Changes Versus Prior Period
The filing does not report operational or financial performance changes compared to a prior period. The material change is the reduction in the Company's cash reserves by approximately $250 million due to the share repurchase and the reduction in the Selling Stockholders' equity position.
Guidance, Outlook, and Risks
- Management Commentary: The filing references press releases issued on February 4 and February 5, 2016, regarding the launch and pricing of the offering, but does not include forward-looking guidance or operational outlook within the text of this report.
- Risks and Contingencies: The Company agreed to indemnify the Underwriter against certain liabilities on customary terms. The Underwriter and its affiliates have provided and may continue to provide commercial banking and financial advisory services to the Company.
- Unusual Items: The transaction was executed pursuant to an existing stockholders agreement that permits the Selling Stockholders to designate two members of the Company's board of directors.
Important Facts for Investor Verification
- Verify the exact share price per share for the $250 million repurchase (calculated as approximately $96.16 per share based on the aggregate price and share count).
- Confirm the updated ownership percentage of the Selling Stockholders post-transaction.
- Review the attached Underwriting Agreement (Exhibit 1.1) for specific covenants and indemnification terms.
- Check the referenced press releases (Exhibits 99.1 and 99.2) for any additional context on the strategic rationale for the repurchase.